ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, ANI Pharmaceuticals, Inc. keeps $12 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
ANI Pharmaceuticals beat expectations on both the top and bottom line in the third fiscal quarter of 2026, reported November 5, 2026, with revenue of $290.8 million topping the $280.6 million estimate (+3.6%) as revenue rose ~28% from about $227.8 million a year ago, reflecting its mix of specialty and generic medicines. Adjusted EPS of $2.70 topped the $2.18 estimate (+23.9%) and was up from $2.04 a year ago, alongside net income that climbed ~46% to roughly $35.1 million from about $24.1 million. Profitability remained elevated, with gross margin at roughly 62% and operating margin near 18%, while operating income came in at about $52.4 million. The quarter also generated about $83.8 million of operating cash flow, and the company repurchased roughly $7.9 million of stock. For the next period, consensus calls for EPS of $2.80 on revenue of $319.5 million.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. develops and markets specialty and generic medicines and manufactures a broad range of dose forms, from injectables and softgel capsules to oral solid doses, semi-solids, liquids, topicals, controlled substances, and potent products. Listed on NASDAQ as ANIP, the company operates in pharmaceuticals and generated $883.4 million of revenue in FY2025.
Today's Snapshot
ANIP closed 0.8% below yesterday's close, while its sector was flat. Shares changed hands at about two-fifths of its usual level.
Trading Volume
Below 10d avg (526.1K)
217.9K
vs S&P 500 Today
Outperforming Market
+2.65%
Updated: November 20, 2026 at 21:25 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$70.15 - $76.27Sell
- RSI (14)41.30Neutral
- Stochastic %K (14, 3, 3)29.08Neutral
- MACD Level (12, 26)-0.71Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.